For over two decades, a ‘treatment-risk paradox’ has been described in older adults with cardiovascular disease, with ...

or large non-ST elevation myocardial infarction (NSTEMI). Study subjects were randomized within 72 hours of PCI to either ...

In updated American recommendations for the management of acute coronary syndrome (ACS), bleeding reduction strategies on antiplatelet therapy are embraced, as are non-statin lipid-lowering therapies ...

Following cardiac catheterization, patients with ST-segment elevation myocardial infarction (STEMI) have a higher risk of short-term mortality than patients with non-STEMI (NSTEMI), who have a ...

More importantly, and less well described in the literature, is how this risk:benefit ratio plays out for patients with NSTEMI or for patients with ACS. As in the case of STEMI, the outcome of DES ...

For patients with either NSTEMI or STEMI, American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend that intravenous unfractionated heparin (UFH) be dosed by weight ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...

The American College of Cardiology and the American Heart Association today released an updated clinical practice guideline for managing individuals experiencing acute coronary syndrome (ACS). The ...

Individual patient data were obtained from three trials, including 9130 randomized patients with ACS: 3132 with ST-segment elevation myocardial infarction (STEMI); 3023 with non-STEMI (NSTEMI ...